RxDoctor Payments Data

Stephen Buckner, APRN

Family · Louisville, KYNPI 1598171563

Payments from drug & device makers

$798in general payments, 2019–2025

Across 38 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$186
  • Actelion Pharmaceuticals US, Inc.$167
  • Boehringer Ingelheim$115
  • AstraZeneca$113
  • Grifols USA, LLC$69
  • Takeda Pharmaceuticals U.S.A., Inc.$25
  • plus $124 from 7 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,532
Medicare patients
102
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$37,281
OzempicSemaglutide17$26,543
Oxtellar XrOxcarbazepine21$22,064
JardianceEmpagliflozin11$10,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,047
Pulmicort FlexhalerBudesonide13$5,335
Divalproex Sodium15$1,934
Levetiracetam18$1,886
Azelastine Hcl39$1,558
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,469
Albuterol Sulfate HfaAlbuterol Sulfate47$1,337
Atorvastatin Calcium182$1,291
Mirtazapine35$1,072
Duloxetine Hcl45$1,053
Rosuvastatin Calcium93$1,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$37,28141 claims
Boehringer IngelheimJardiance$115$10,50811 claims
AstraZenecaPulmicort Flexhaler$113$5,33513 claims
AbbVieSynthroid$186$44311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →